Eli Lilly vs. Novo Nordisk: Which Stock Has the Edge Right Now?

TLDR Novo Nordisk’s oral Wegovy pill achieved 3,071 retail prescriptions within four days of its January 5, 2026 launch Novo’s shares rose 6.5% to their highest level since September 2025 following the prescription data release Eli Lilly’s Zepbound injection currently dominates weight loss market sales with FDA decision on Lilly’s oral pill expected by April [...]

The post Eli Lilly vs. Novo Nordisk: Which Stock Has the Edge Right Now? appeared first on Blockonomi.